We will relentlessly pursue treatments targeting SGK1 to enable people to live their absolute best lives.
Without Limits.
Announcement: Thryv Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, taking place January 13-16, 2025. Read More. To arrange a meeting with Thryv, please contact us at admin@thryvtrx.com.
Our Focus:
Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1).
Isla Hutton
Long QT Type 3
We gain momentum everyday in our relentless pursuit of a treatment for Long QT Syndrome - In memory of Isla.
Together We Thryv
The enthusiasm of our investors is a reflection of breakthrough science, hard work and the dedication of our scientists, founders and collaborators.
Together we share a vision to transform the lives of people with life-threatening conditions.
Follow our journey
